PPARA and Cirrhosis: Among the various drugs targeting different PPAR isoforms, the pan-PPAR agonist lanifibranor, an indole sulfonamide derivative, has garnered considerable attention due to studies demonstrating its significant effects in experimental models of cirrhosis, highlighting its potential therapeutic value [286].